In the ICON7 trial studying the addition of bevacizumab to standard carboplatin-paclitaxel chemotherapy for ovarian cancer, bevacizumab showed significant improvement in progression-free survival only in which subgroup?
- A High-risk patients defined as those with Stage IV disease or Stage III with suboptimal cytoreduction (residual disease >1 cm) ✓
- B All patients with Stage III–IV disease regardless of cytoreduction status
- C Only BRCA-mutated patients who received maintenance bevacizumab
- D Only patients under 60 years with high-grade serous histology
Correct answer: A. High-risk patients defined as those with Stage IV disease or Stage III with suboptimal cytoreduction (residual disease >1 cm)
Explanation
The ICON7 trial demonstrated that the addition of bevacizumab to carboplatin-paclitaxel and as maintenance improved progression-free survival in the overall cohort modestly, but the most significant and clinically meaningful benefit was seen in the high-risk group: Stage IV disease or Stage III with residual disease >1 cm after cytoreduction. This subgroup showed a prolonged overall survival benefit as well. Based on these findings, bevacizumab is incorporated into first-line treatment for high-risk advanced ovarian cancer.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.